Metavia Inc (MTVA) Stock Price, Quote & News

Company Profile

MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomod...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 702 9600

Website: www.metaviatx.com

Address:

545 Concord Avenue, Suite 210, Cambridge, United States

Jw242 Feb. 23 at 3:49 PM

$MTVA added. Sorry the longs here have been killed but it’s a traders stock

0 · Reply

BreakoutPika Feb. 23 at 12:26 PM

$MTVA $IMG $STRO $XHLD ∆

0 · Reply

Kinderla Feb. 23 at 12:08 PM

$IBG $MTVA IBG is a small Australia-based beverage company (founded 2019, public Sep 2024) trading near $4.50 with a ~$3.2M MC and over $2M annual revenue. The company plans to merge with BlockFuel Energy, a private Texas oil and gas firm focused on converting stranded natural gas into power for BTC miners and data centers. Under the Feb 11 update (https://shorturl.at/Szr38), IBG holders would own ~10% of the combined company, with BlockFuel valuations estimated around $200M–$350M which would imply an 6x to 10x increase from the current MC. The merger makes strategic sense: BlockFuel gains a reverse IPO/Nasdaq listing, while IBG gains capital and a new direction. The key link is CEO Dan Lanskey, who leads BlockFuel and sits on IBG’s board, with prior Oklahoma oil &amp;; gas startup experience. This should do a 2x to 5x or more in short order.

0 · Reply

Kertzi Feb. 23 at 8:46 AM

$MTVA Here is MetaVia Inc. Hyung Heon Kim (CEO): Dong-ST sent their lawyer to US to become the CEO of MetaVia to ensure their interests were 100% taken care of. Rihyun Kim, who is clearly there to look after Dong-ST's interests as well. The company's third financial (dilution) expert is Marshall Woodworth, the CFO - He is paid handsomely to keep his mouth shut. Since the company survives solely by printing shares, someone dedicated to writing SEC filings is needed: Tony Wong is responsible for this task. The rest of the "employees" play supporting roles.

1 · Reply

Kertzi Feb. 23 at 4:50 AM

$MTVA Take a close look at this crew and ask yourself: Do I see a dream team, that can take this "company" to new heights?

0 · Reply

Kinderla Feb. 20 at 7:33 PM

$IBG $MTVA IBG is a small Australia-based beverage company (founded 2019, public Sep 2024) trading near $4.50 with a ~$3.2M MC and over $2M annual revenue. The company plans to merge with BlockFuel Energy, a private Texas oil and gas firm focused on converting stranded natural gas into power for BTC miners and data centers. Under the Feb 11 update (https://shorturl.at/Szr38), IBG holders would own ~10% of the combined company, with BlockFuel valuations estimated around $200M–$350M which would imply an 6x to 10x increase from the current MC. The merger makes strategic sense: BlockFuel gains a reverse IPO/Nasdaq listing, while IBG gains capital and a new direction. The key link is CEO Dan Lanskey, who leads BlockFuel and sits on IBG’s board, with prior Oklahoma oil &; gas startup experience. This should do a 2x to 5x or more in short order.

0 · Reply

Shodan84 Feb. 20 at 2:41 PM

$MTVA See you in orbit on Wednesday :)

2 · Reply

Kinderla Feb. 19 at 7:43 PM

$MTVA Let me suggest an alternative, lower risk and higher reward play that you won't have to wait until the end of 2026 to see come to fruition: IBG IBG is a small Australia-based beverage company (founded 2019, public Sep 2024) trading near $4.50 with a ~$3.2M MC and over $2M annual revenue. The company plans to merge with BlockFuel Energy, a private Texas oil & gas firm focused on converting stranded natural gas into power for BTC miners and data centers. Under the Feb 11 update (https://shorturl.at/Szr38), IBG holders would own ~10% of the combined company, with BlockFuel valuations estimated around $200M–$350M which would imply an 6x to 10x increase from the current MC. The merger makes strategic sense: BlockFuel gains a reverse IPO/Nasdaq listing, while IBG gains capital and a new direction. The key link is CEO Dan Lanskey, who leads BlockFuel and sits on IBG’s board, with prior Oklahoma oil & gas startup experience. This is much better than MTVA.

1 · Reply

Sasuke22x Feb. 19 at 5:34 PM

$PSNY $WKHS $TGL $MTVA /

0 · Reply

VolatilityArbitrageur Feb. 18 at 4:21 PM

$MTVA MetaVia is a biotech with metabolic disease focus. Clinical execution drives valuation. Development timelines are long.

1 · Reply

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference

Feb 13, 2026, 12:39 PM EST - 11 days ago

MetaVia Secures Dozens Of Patents Through 2041 For Obesity Drug

Feb 13, 2026, 8:31 AM EST - 11 days ago

MetaVia Builds Comprehensive Global Patent Protection for DA-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 2041

Feb 4, 2026, 8:00 AM EST - 20 days ago

MetaVia Announces Positive AI-Modeling Results from its Ongoing Syntekabio Collaboration, Confirming Key Therapeutic Targets for Vanoglipel

Jan 16, 2026, 4:01 PM EST - 5 weeks ago

MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option

Jan 15, 2026, 9:32 AM EST - 5 weeks ago

MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering

Jan 5, 2026, 8:30 AM EST - 7 weeks ago

MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss and Favorable Safety Profile

Dec 29, 2025, 8:31 AM EST - 2 months ago

MetaVia to Participate in and Sponsor the 10th Annual MASH-TAG 2026 Conference

Dec 22, 2025, 8:31 AM EST - 2 months ago

MetaVia Regains Compliance with Nasdaq Minimum Bid Price Requirement

Dec 2, 2025, 8:45 AM EST - 3 months ago

MetaVia Inc. Announces 1-for-11 Reverse Stock Split

Nov 7, 2025, 8:31 AM EST - 3 months ago

MetaVia Presents Positive New Phase 2a Data on Vanoglipel (DA-1241) in Patients with Presumed MASH at the AASLD The Liver Meeting® 2025

Nov 6, 2025, 8:31 AM EST - 3 months ago

MetaVia Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 4, 2025, 4:01 PM EST - 3 months ago

MetaVia to Present New Phase 1 and Pre-Clinical Data on DA-1726 at ObesityWeek® 2025

Oct 27, 2025, 8:31 AM EDT - 4 months ago

MetaVia Announces Poster Presentation on Vanoglipel (DA-1241) at the AASLD Liver Meeting

Oct 20, 2025, 8:31 AM EDT - 4 months ago

MetaVia Announces Poster Presentations on DA-1726 at ObesityWeek® 2025

Oct 14, 2025, 8:31 AM EDT - 4 months ago

MetaVia to Present at the H.C. Wainwright Liver Disease Virtual Conference

Aug 26, 2025, 8:31 AM EDT - 6 months ago

MetaVia to Present at Upcoming Investor and Industry Conferences

Aug 7, 2025, 8:31 AM EDT - 7 months ago

MetaVia Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 6, 2025, 8:31 AM EDT - 7 months ago

MetaVia Extends 48 mg MAD Portion of Its Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity to 8 Weeks and Announces Fifth Weekly Dose in First Patient

Aug 4, 2025, 8:31 AM EDT - 7 months ago

MetaVia Announces AI-Driven Collaboration with Syntekabio to Explore Additional Indications for DA-1241

Jul 9, 2025, 8:31 AM EDT - 8 months ago

MetaVia Doses First Patient in the 48 mg MAD Cohort of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity to Further Explore Maximum Tolerated Dose

Jun 21, 2025, 9:00 AM EDT - 8 months ago

MetaVia Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA's 85th Scientific Session

Jun 10, 2025, 8:31 AM EDT - 9 months ago

MetaVia to Present at the Life Sciences Virtual Investor Forum June 12th

Jun 4, 2025, 8:31 AM EDT - 9 months ago

MetaVia Announces Poster Presentation on DA-1241 at the ADA's 85th Scientific Sessions

May 14, 2025, 4:05 PM EDT - 10 months ago

MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 9, 2025, 8:01 AM EDT - 10 months ago

MetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules

May 7, 2025, 2:00 AM EDT - 10 months ago

MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025

Apr 23, 2025, 8:31 AM EDT - 10 months ago

MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025

Apr 22, 2025, 8:31 AM EDT - 11 months ago

MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class Potential

Apr 15, 2025, 7:01 AM EDT - 11 months ago

MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerability

Mar 20, 2025, 7:31 AM EDT - 1 year ago

MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update

Jan 10, 2025, 8:05 AM EST - 1 year ago

MetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 Conference

Nov 18, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases

Nov 13, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals to Participate in Investor Conferences in November

Nov 7, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 4, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Oct 1, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals to Participate in Investor Conferences in October

Sep 30, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Sep 3, 2024, 8:01 AM EDT - 1 year ago

NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Aug 14, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 13, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Aug 6, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity

Jul 30, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01

Jul 11, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals to Present at the Emerging Growth Conference in July

Jun 26, 2024, 9:06 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Jun 25, 2024, 5:08 PM EDT - 1 year ago

NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 24, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Announces up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 22, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals' DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical Models

May 22, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals' DA-1241 in Combination with Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical MASH Models Compared to Either Treatment, Alone

May 9, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

Jw242 Feb. 23 at 3:49 PM

$MTVA added. Sorry the longs here have been killed but it’s a traders stock

0 · Reply

BreakoutPika Feb. 23 at 12:26 PM

$MTVA $IMG $STRO $XHLD ∆

0 · Reply

Kinderla Feb. 23 at 12:08 PM

0 · Reply

Kertzi Feb. 23 at 8:46 AM

1 · Reply

Kertzi Feb. 23 at 4:50 AM

$MTVA Take a close look at this crew and ask yourself: Do I see a dream team, that can take this "company" to new heights?

0 · Reply

Kinderla Feb. 20 at 7:33 PM

$IBG $MTVA IBG is a small Australia-based beverage company (founded 2019, public Sep 2024) trading near $4.50 with a ~$3.2M MC and over $2M annual revenue. The company plans to merge with BlockFuel Energy, a private Texas oil and gas firm focused on converting stranded natural gas into power for BTC miners and data centers. Under the Feb 11 update (https://shorturl.at/Szr38), IBG holders would own ~10% of the combined company, with BlockFuel valuations estimated around $200M–$350M which would imply an 6x to 10x increase from the current MC. The merger makes strategic sense: BlockFuel gains a reverse IPO/Nasdaq listing, while IBG gains capital and a new direction. The key link is CEO Dan Lanskey, who leads BlockFuel and sits on IBG’s board, with prior Oklahoma oil &; gas startup experience. This should do a 2x to 5x or more in short order.

0 · Reply

Shodan84 Feb. 20 at 2:41 PM

$MTVA See you in orbit on Wednesday :)

2 · Reply

Kinderla Feb. 19 at 7:43 PM

1 · Reply

Sasuke22x Feb. 19 at 5:34 PM

$PSNY $WKHS $TGL $MTVA /

0 · Reply

VolatilityArbitrageur Feb. 18 at 4:21 PM

$MTVA MetaVia is a biotech with metabolic disease focus. Clinical execution drives valuation. Development timelines are long.

1 · Reply

Kertzi Feb. 18 at 3:14 PM

$MTVA "Emerging Growth Conference"

0 · Reply

BreakoutPika Feb. 18 at 12:33 PM

$TGL $MTVA $IMG $STRO ×

0 · Reply

SkyLonger Feb. 18 at 11:58 AM

$MTVA weird prints, squeeze time?

0 · Reply

2xSasuke Feb. 17 at 6:17 PM

$TGL $MTVA $IMG $STRO 7

0 · Reply

ScoobyDoo_Esquire Feb. 17 at 3:29 PM

$MTVA Another small position added at $1.49 — I don’t like how sporadic this stock moves. The setup is worth participation though.

1 · Reply

Kertzi Feb. 17 at 3:00 PM

$MTVA is trading lower than before the reverse split at a ratio of 1:11. YTD -85%, yes, you have 15 cents left from a dollar. The chart history is just sickening—thousands to pennies. The next time you see it trading above $10 will be after the next R/S.

1 · Reply

Joefreeagent Feb. 17 at 2:54 PM

$MTVA it's coiling up, buying the dip, tp $220 lmao. This is heading back to .72 cents in record time.

0 · Reply

MrTicker Feb. 17 at 2:03 PM

$MTVA https://www.prnewswire.com/news-releases/metavia-to-highlight-novel-obesity-and-metabolic-therapies-at-upcoming-emerging-growth-conference-302688425.html

0 · Reply

MrTicker Feb. 17 at 2:03 PM

$MTVA MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference PR NEWSWIRE 8:01 AM ET 2/17/2026

0 · Reply

BreakoutPika Feb. 17 at 1:18 PM

$TGL $MTVA $IMG __

0 · Reply

PennySearch Feb. 15 at 6:45 PM

$MTVA -1% | 11.7x RVOL Extreme abnormal activity.

2 · Reply

DJORCKO Feb. 13 at 9:04 PM

$MTVA sold $RIME to buy $MTVA .... Hahahhahahaha what a mistake i made

1 · Reply

Market Cap	3.41M
Revenue (ttm)	0.00
Net Income (ttm)	-27.59M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	35,073
Avg Vol	253,790
Day's Range	N/A - N/A
Shares Out	2.20M
Stochastic %K	15%
Beta	0.27
Analysts	Strong Sell
Price Target	$51.67